NanoString

NanoString Technologies, now part of Somasphere, developed and commercialized a ncounter-based gene expression, protein, and cell type analysis platform. This platform offered a method for high-throughput, multiplexed analysis without the need for amplification. The core technology involved directly counting individual molecules of RNA or protein within a sample. This was achieved by binding target molecules to specific reporter molecules, which were then immobilized on a surface and illuminated. Each reporter molecule carried a unique fluorescent barcode, allowing for the simultaneous detection and quantification of hundreds of different targets.

The ncounter system was designed to provide researchers with precise and accurate measurements of gene and protein expression levels. It was utilized in various fields, including basic research, drug discovery, and clinical diagnostics. The platform's ability to analyze multiple targets simultaneously and its high sensitivity made it a valuable tool for understanding complex biological systems and identifying biomarkers. NanoString's technology aimed to streamline the process of molecular analysis, offering an alternative to traditional methods. The company was acquired by Somasphere in 2023, integrating its technologies into Somasphere's broader offerings.